Greifswald, 1 June 2026The globally active CHEPLAPHARM Group, a leading international pharmaceutical platform for established branded medicines, has a new Chief Financial Officer (CFO): Martin Krämer takes up the post with immediate effect, thereby strengthening the financial organisation of the Greifswald-based company. Martin Krämer joins CHEPLAP [ … ]

Greifswald, May 18, 2026The globally active CHEPLAPHARM Group, one of the world’s leading companies in the acquisition of original products from the research-based pharmaceutical industry, is systematically aligning its Management Board for the company’s next phase of growth. Following a period of transformation, operational stabilization and organ [ … ]

Greifswald, April 29, 2026 Revenue grew by +8.1% year-on-year to €1,658.4 million (FY2024: €1,534.6 million) EBITDA at €642.8 million, roughly on a par with the previous year EBITDA margin at 38.8%, remaining at an industry-leading level The number of employees rose slightly to 799 – an increase of 2% (FY2024: 785) The globally active CHEPLAPHA [ … ]

Greifswald, Germany, February 2, 2026CHEPLAPHARM Arzneimittel GmbH ("CHEPLAPHARM"), a leading international pharmaceutical platform for established branded medicines, announces the successful placement of €950m of senior secured notes at an interest rate of 6.750%. The proceeds from the new notes will be used for the early redemption in full of two [ … ]